BioCentury | Feb 11, 2013
Company News

Aduro Biotech, BioSante deal

...will also assume rights to BioSante's existing license agreement for GVAX melanoma vaccine with the John P. Hussman Foundation...
BioCentury | Jul 25, 2011
Company News

BioSante, John P. Hussman Foundation deal

...for up to $39 million in milestones and 15-33% of sublicense revenues, plus royalties. The Hussman Foundation...
...to treat stage IIb-IV melanoma (see BioCentury, Jan. 31). BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. John P. Hussman Foundation...
Items per page:
1 - 2 of 2
BioCentury | Feb 11, 2013
Company News

Aduro Biotech, BioSante deal

...will also assume rights to BioSante's existing license agreement for GVAX melanoma vaccine with the John P. Hussman Foundation...
BioCentury | Jul 25, 2011
Company News

BioSante, John P. Hussman Foundation deal

...for up to $39 million in milestones and 15-33% of sublicense revenues, plus royalties. The Hussman Foundation...
...to treat stage IIb-IV melanoma (see BioCentury, Jan. 31). BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. John P. Hussman Foundation...
Items per page:
1 - 2 of 2